Yanjuan He
Overview
Explore the profile of Yanjuan He including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
565
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zhu Y, Yang Q, Yang Q, He Y, Zhou W
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190210
Hematological malignancies are diverse, with high malignancy characteristics, poor prognoses, and high mortality rates. The development of hematological malignancies is driven by genetic factors, tumor microenvironment factors, or metabolic factors;...
12.
Kuang C, Xia M, An G, Liu C, Hu C, Zhang J, et al.
Nat Commun
. 2023 Apr;
14(1):2093.
PMID: 37055385
Thrombocytopenia is a major complication in a subset of patients with multiple myeloma (MM). However, little is known about its development and significance during MM. Here, we show thrombocytopenia is...
13.
Yang Q, Wei Y, Zhu Y, Guo J, Zhang J, He Y, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046603
Although novel therapies have dramatically improved outcomes for multiple myeloma (MM) patients, relapse is inevitable and overall outcomes are heterogeneous. The gut microbiota is becoming increasingly recognized for its influence...
14.
Hong L, Zang X, Hu Q, He Y, Xu Z, Xie Y, et al.
J Nanobiotechnology
. 2023 Mar;
21(1):79.
PMID: 36882792
Most pregnancy losses worldwide are caused by implantation failure for which there is a lack of effective therapeutics. Extracellular vesicles are considered potential endogenous nanomedicines because of their unique biological...
15.
Zhang J, Shi F, Liu X, Wu X, Hu C, Guo J, et al.
Br J Haematol
. 2023 Feb;
201(4):704-717.
PMID: 36755409
Amino acids in the bone marrow microenvironment (BMME) are a critical factor for multiple myeloma (MM) progression. Here, we have determined that proline is elevated in BMME of MM patients...
16.
Wang Y, Yang Q, Zhu Y, Jian X, Guo J, Zhang J, et al.
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077725
Pneumonia accounts for a significant cause of morbidity and mortality in multiple myeloma (MM) patients. It has been previously shown that intestinal () enriches in MM and promotes MM progression....
17.
He Y, He H, Tang C
Comput Math Methods Med
. 2022 Sep;
2022:6206851.
PMID: 36051001
Objective: To study the effects of psychological nursing intervention on anxiety, depression, and life events in puerperal women with fetal abnormalities. Methods: From January 2020 to January 2022, eighty women...
18.
Zhou H, Yin Q, Jin J, Liu T, Cai Z, Jiang B, et al.
Hematology
. 2022 Aug;
27(1):917-927.
PMID: 36000952
Objectives: The prognosis for adults with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is poor. Blinatumomab is a CD3/CD19-directed BiTE® (bispecific T-cell engager) molecule approved globally for the treatment...
19.
Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance
Xia J, Zhang J, Wu X, Du W, Zhu Y, Liu X, et al.
Nat Commun
. 2022 Jul;
13(1):4007.
PMID: 35817773
Metabolites in the tumor microenvironment are a critical factor for tumor progression. However, the lack of knowledge about the metabolic profile in the bone marrow (BM) microenvironment of multiple myeloma...
20.
Liu F, Cheng Q, Song K, Yu H, Li J, Zhang H, et al.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
. 2022 May;
47(4):497-504.
PMID: 35545345
Objectives: There is less clinical data on multiple myeloma (MM) in China, and the aim of this study was to collect and analyze the clinical data of newly diagnosed multiple...